CARsgen Therapeutics Holdings Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Zonghai Li
Chief executive officer
CN¥2.1m
Total compensation
| CEO salary percentage | 50.2% |
| CEO tenure | 3.9yrs |
| CEO ownership | n/a |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is CARsgen Therapeutics Holdings (HKG:2171) Weighed On By Its Debt Load?
Dec 04
Is CARsgen Therapeutics Holdings (HKG:2171) Using Debt Sensibly?
Aug 31CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans
Jan 23Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth
Sep 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥695m |
| Mar 31 2024 | n/a | n/a | -CN¥721m |
| Dec 31 2023 | CN¥2m | CN¥1m | -CN¥748m |
| Sep 30 2023 | n/a | n/a | -CN¥834m |
| Jun 30 2023 | n/a | n/a | -CN¥920m |
| Mar 31 2023 | n/a | n/a | -CN¥906m |
| Dec 31 2022 | CN¥2m | CN¥1m | -CN¥892m |
Compensation vs Market: Zonghai's total compensation ($USD287.54K) is below average for companies of similar size in the Hong Kong market ($USD466.13K).
Compensation vs Earnings: Zonghai's compensation has increased whilst the company is unprofitable.
CEO
Zonghai Li (50 yo)
3.9yrs
Tenure
CN¥2,084,000
Compensation
Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.9yrs | CN¥2.08m | no data | |
| Co-Founder | 3.9yrs | CN¥2.11m | no data | |
| Executive Director | 2.4yrs | CN¥1.39m | no data | |
| Senior Vice President of Clinical Development | no data | no data | no data | |
| Senior Vice President of Business Development | no data | no data | no data | |
| Chief Medical Officer | 2.8yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs | 2.3yrs | no data | no data | |
| Company Secretary | 3.9yrs | no data | no data |
3.3yrs
Average Tenure
51yo
Average Age
Experienced Management: 2171's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.9yrs | CN¥2.08m | no data | |
| Co-Founder | 6.3yrs | CN¥2.11m | no data | |
| Executive Director | 2.4yrs | CN¥1.39m | no data | |
| Non-Executive Director | 4.3yrs | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | CN¥80.00k | no data | |
| Non-Executive Director | 6.3yrs | no data | 1.62% HK$ 89.6m | |
| Independent Non-Executive Director | 3.6yrs | CN¥222.00k | no data | |
| Non-Executive Director | 4.3yrs | no data | 0.38% HK$ 20.9m | |
| Independent Non-Executive Director | less than a year | no data | no data |
4.3yrs
Average Tenure
47yo
Average Age
Experienced Board: 2171's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 15:55 |
| End of Day Share Price | 2025/01/28 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CARsgen Therapeutics Holdings Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Ziyi Chen | Goldman Sachs |